Degarelix: A New Approach For The Treatment Of Prostate Cancer

Main Category: Prostate / Prostate Cancer Also Included In: Urology / Nephrology ; Cancer / Oncology Article Date: 16 Nov 20094:00 PST UroToday.comGonadotrophin-releasing hormone agonists are currently the ’standard of care’ for androgen deprivation therapy in prostate cancer .

source : www.topix.com

Related News:

• Kidney Cancer Drug Shows Promising Results
• Launch Of Ipsen’s Decapeptyl(R) 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Prostate Cancer
• Barker Hypothesis Strengthened By Ancient Tooth Remains
• Scientists At Rice University Discover That ‘Nanobubbles’ Kill Cancer
• AM: Opioid Gains Long-Term Control of Neuropathic Cancer Pain (CME/CE)
• Launch Of Ipsen’s Decapeptyl 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Advanced Or Metastatic Hormone-Dependent Prostate Cancer
• Green Tea Extracts Halt Growth of Prostate Cancer Tumors
• AM: Opioid Shows Long-Term Control of Neuropathic Cancer Pain (CME/CE)
• Recordati : Silodosin Approved By The European Commission For The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia
• EMEA Gives Official Scientific Advice On Clinical Phase IIb Efficacy Study Of Inecalcitol In Hormone-refractory Prostate Cancer

Details :
Submited at Monday, November 16th, 2009 at 7:00 pm on Urology by Gillan
Comment RSS 2.0 - leave a comment - trackback